Previous Close | 2.2800 |
Open | 2.2500 |
Bid | 2.0000 x 1000 |
Ask | 0.0000 x 800 |
Day's Range | 2.2000 - 2.2700 |
52 Week Range | 1.8500 - 5.0000 |
Volume | |
Avg. Volume | 106,720 |
Market Cap | 193.175M |
Beta (5Y Monthly) | 1.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2400 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.19 |
Subscribe to Yahoo Finance Plus to view Fair Value for IMMP
Immutep Limited (NASDAQ: IMMP) announced new interim data from 2nd line non-small cell lung cancer (NSCLC) patients (Part B) in the Phase 2 TACTI-002 trial. Part B evaluates Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in 36 patients. Median overall survival (OS) was 9.7 months for those who received chemo-free therapy of efti in combination with pembrolizumab, comparable with the current standard
Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 / anti-PD-L1 (“PD-X”) based 1st line therapy1Key facts reported: Median Overall Survival (OS) from therapy with efti in combination with pembrolizumab is 9.7 months25% were progression free at 6 months and 36.5% were alive at 18 months2 Chemo-free therapy of efti in combination with pembrolizumab contin
Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activityBiomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longerFour world leading oncologists join the Clinical Advisory BoardWell-funded with ~$80 million in cash, giving Immutep an expected cash runway into early